anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Control-Experimental Arm will undergo the Control Admission first, utilizing an artificial pancreas (AP) controller that does not anticipate exercise (rMPC - naïve model predictive control), followed by the Experimental Admission, which will utilize an AP controller that has the ability to anticipate exercise (EnMPC - ensemble model predictive control). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
This study is a non-randomized, single-arm, single-institutional phase II study including patients with Locally Advanced Head and Neck Squamous Cell Carcinoma eligible for resection. Nab-paclitaxel (260 mg/m² IV), cisplatin (75 mg/m² IV), and Pembrolizumab (200 mg IV) will be administered for two cycles of three weeks duration each. Surgery or CRT will be performed after induction therapy. Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive CRT. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment. Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly. After surgery, adjuvant CRT will be given for patients with high-risk factors. Objective response rate, safety, and rate of organ preservation will be the primary outcome measures.
Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
A no-exercise control. Must maintain \<4,500 steps per day for 3 consecutive days followed by a high fat tolerance test on day 4.
This trial aims to demonstrate that the use of darolutamide (in addition to standard of care) will be more effective than current standard of care in enhancing the ability of prostate or prostate bed radiation and 96 weeks of androgen suppression in decreasing the number of patients who develop metastases and subsequently die of prostate cancer. Darolutamide is a novel antagonist of the AR with favourable tolerability due to negligible penetration of the blood-brain barrier. Emergence of metastatic disease is the lethal event after local therapy, either with prostatectomy or definitive radiation. Augmenting adjuvant systemic therapy (either ADT or ADT plus docetaxel) with darolutamide has the potential to eradicate micrometastatic disease after either type of local therapy and decrease the death rate from prostate cancer.

This pragmatic design incorporates current standard of care for all patients and the option for docetaxel to be added to ADT. As such, the data will be applicable for all patients with very high risk prostate cancer treated with local therapy and will be the first study incorporating docetaxel use as one of the standard of care options. Even if docetaxel is definitively proven to improve MFS and OS in the adjuvant setting, not all patients will be fit for docetaxel. This will be the first trial that has the potential to build upon current and future advances that may emerge and be the most effective strategy to decrease death rate from prostate cancer in the near term if it further augments docetaxel efficacy in chemo-fit patients.
Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
Walking with age becomes both slower and less 'automated', requiring more attention and prefrontal resources. As a result older adults have a greater risk of adverse mobility outcomes and falls. Walking disturbances in the elderly have been linked to changes in both cerebral, in particular small vessel disease (cSVD), and peripheral systems. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Although effective mobility is the end result of the functional capacity of both central and peripheral systems, the brain's unique modulatory and adaptive capacity may provide clues for novel interventions. For example, investigators have recently discovered that \~20% of older adults maintain fast walking speed even in the presence of age related cSVD and peripheral system impairments, thus appearing resilient to these harmful factors. The investigators work suggests that the nigrostriatal dopamine (DA) system may be a source of this resilience. As investigators recent findings suggest, DA neurotransmission positively predicts walking speed; it also attenuates the negative effects of age related cSVD and peripheral system impairments on walking speed. These findings are consistent with post-mortem evidence that a combination of loss of nigral DA neurons and cSVD best predict age-related walking impairment. The nigrostriatal DA system plays a critical role in motor control; nigrostriatal. DA neurotransmission regulates the automated execution of overlearned motor tasks via its connections with sensorimotor cortical and subcortical areas.

The investigators hypothesize that higher nigrostriatal DA neurotransmission drives resilience to cSVD and peripheral system impairments, via higher connectivity of sensorimotor networks, thus increasing automaticity of walking and reducing prefrontal engagement while walking. Unlike cSVD and brain structural impairments, DA neurotransmission is potentially modifiable, thereby offering novel approaches to treat non-resilient elderly in a targeted fashion. This study is an arm of a previously completed translational pilot biomechanistic target engagement study in older adults with slow walking and/or parkinsonian signs (NCT04325503). This sub-study will further investigate this biomechanistic target engagement using a double-blind, placebo-controlled study design.

The study will include elderly men and women age 60 or older with evidence of mild parkinsonian signs (MPS, or slow gait (\< 1m/s)).
The invention discloses a Chinese medicinal composition for treating chronic pharyngitis. The Chinese medicinal composition for treating chronic pharyngitis consists of the following components in parts by weight: 10-30 parts of giant knotweed, 5-10 parts of dutchmanspipe fruit, 5-10 parts of pinellia tuber, 5-10 parts of unibract fritillary bulb, 5-15 parts of vervain, 5-15 parts of discolor cinquefoil herb, 5-15 parts of honeysuckle stem, 5-15 parts of paris rhizome, 5-15 parts of meadowrue root and rhizome, 5-10 parts of fingered citron, 15-25 parts of sophora flower and 5-10 parts of rhubarb. The Chinese medicinal decoction for treating chronic pharyngitis is prepared according to the theory of traditional Chinese medicine. By combining the traditional Chinese medicines, the synergistic effect of treating chronic pharyngitis is achieved. The Chinese medicinal preparation is small in toxic and side effects and low in cost. By adopting ultrafine smashing, the availability of effective components is improved.
Because H. pylori is an enteric infection, its prevalence may be linked to exposure to other enteric pathogens. Results of observational studies on the association between H. pylori and gastroenteritis, however, have been conflicting. Some have shown increased incidence of diarrhea in children with H. pylori infection, with one study attributing 11% of diarrhea cases to H. pylori. Other studies found no association, and still others found a protective effect of H. pylori against gastroenteritis. Dissecting out confounding from true physiological associations can be difficult in observational studies. To better elucidate the association between H. pylori and gastroenteritis, we performed a direct challenge experiment with a well-characterized gastrointestinal pathogen, enteropathogenic Escherichia coli (EPEC). EPEC is a leading cause of infantile gastroenteritis in the world and has a long history of safe use in human experiments. It is also acid sensitive: in our laboratory less than 0.001% of inoculated EPEC organisms survived at pH 2.5. Our goal was to test the hypothesis that chronic infection with H. pylori increases the risk of diarrheal illness after direct challenge with EPEC.
Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
Clinically, there is a critical need for improved therapies in ovarian cancer. There has been recent success with maintenance therapy in ovarian cancer with both PARP inhibitors and bevacizumab approved in the up-front maintenance setting and in the recurrent, platinum sensitive maintenance setting. However, it is unclear what treatment should be used post-PARPi or bevacizumab maintenance. Additionally, the benefit derived from bevacizumab maintenance therapy is modest with generally a few month improvement in progression free survival. Further, there is emerging evidence that after progression on a PARPi, there is decreased response to platinum-based therapy. This provides a critical unmet need to enhance platinum response, particularly after previous maintenance therapy. This also provides a large group of patients who could potentially benefit from EZH2 targeting agents to block stromal-mediated chemotherapy resistance and metastasis.

This study aims to investigate whether CPI-0209 will enhance ovarian cancer sensitivity to platinum-based chemotherapy and prolong the disease free interval after completion of chemotherapy by blocking stromal mediated chemotherapy resistance, metastasis promotion and ovarian cancer growth.
The invention relates to the field of health drink foods, and particularly discloses a formula of trichosanthes kirilowii soup for treating expectoration and a preparation method of the trichosanthes kirilowii soup. The trichosanthes kirilowii soup is prepared from the following raw materials in parts by weight: 30 to 40 parts of water, 50 to 70 parts of trichosanthes kirilowii, 20 to 30 parts of medicated leaven powder, 0.1 to 10 parts of lycium barbarum, 8 to 12 parts of apricot kernels and 5 to 7 parts of onion. The preparation method of the trichosanthes kirilowii soup comprises the following steps: proportioning the raw materials in parts by weight, and then heating for 20 to 30 minutes in a stirring manner until boiling. The invention aims to provide the formula of the trichosanthes kirilowii soup treating expectoration and the preparation method of the trichosanthes kirilowii soup so as to solve the technical defects existing in the prior art. The trichosanthes kirilowii soup is prepared by taking the trichosanthes kirilowii as a main material matched with medicated leaven powder, apricot kernels, onion and grape wine in a heating and stirring manner. The trichosanthes kirilowii soup can be used for treating throat expectoration, ceaseless spitting, body weakness caused by qi deficiency, anorexia and other symptoms. In addition, the trichosanthes kirilowii soup taking the trichosanthes kirilowii as the main material has no medicinal flavor and is sweet in taste, and is low in cost, simple to process and low in price at the same time. Thus, the trichosanthes kirilowii soup is suitable for common people.
BACKGROUND: The deep circumflex iliac artery (DCIA) perforator flap is an established method to reconstruct osteocutaneous defects. However, the cutaneous perforators come with a great anatomic variability. To deal with this problem, we used a sequential chimeric osteocutaneous free flap for reconstruction.
PATIENTS AND METHODS: A 58-year-old man presented with an open tibial fracture after an avalanche accident resulting in an extended osteocutaneous defect in the lower extremity. The injury required osteocutaneous free flap coverage. We reconstructed the defect with a sequential chimeric osteocutaneous DCIA-perforator-SIEA flap.
RESULTS: The preservation of the ascending branch of the deep circumflex iliac vessels offered us the possibility to effectively cover an extended osteocutaneous defect in the lower extremity with a sequential chimeric osteocutaneous DCIA-perforator-SIEA flap. In our patient, the sequential chimeric osteocutaneous DCIA-perforator-SIEA flap healed without complications. A small hernia developed at the inguinal donor site area, but it healed without further complications after surgical treatment. The patient regained an adequate function and returned to daily life and physical exercise.
CONCLUSION: While preparing the DCIA-perforator free flap, it is important to preserve the ascending branch of the deep circumflex iliac vessels and the vessels needed to harvest either a SIEA or SCIP flap.
Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 0.5x PAL, i.e. 30 μg).
The invention discloses a granular preparation for promoting blood circulation, dredging collaterals and relieving pain, a preparation method of the granular preparation, and a quality control method of the Chinese traditional medicine. The granular preparation of the invention is prepared from pharmaceutical excipients and a Chinese traditional medicine composition prepared from the following raw materials in parts by weight: 160-240 parts of white peony root, 40-60 parts of kudzu root, 40-60 parts of peach kernel, 40-60 parts of safflower, 40-60 parts of mastic, 40-60 parts of myrrh, 55-95 parts of teasel root, 55-95 parts of cibot rhizome, 55-95 parts of lycopodium clavatum, 40-60 parts of achyranthes, 40-60 parts of rehmannia and 15-35 parts of licorice. The granular preparation of the invention has stable granulation process and high quality controllability. The clinical test shows that the clinical total effective rate of the granular preparation of the invention for treating cervical spondylosis is 98.88%, the total effective rate of the control medicine for treating cervical spondylosis is 97.10%, and the state of an illness and main symptoms are improved obviously after treating. The effective rate for treating sciatica is 75.3%, the effective rate for treating hyperosteogeny is 82.7%, the effective rate for treating headache and dizziness caused by cervical spondylosis is 87.6%, the effective rate for treating waist pain and limitation of motion is 91.4%, the effective rate for treating shoulder and neck tenderness is 92.5%, the effective rate for treating neck pain and limitation of motion is 96.2%, and the effective rate for treating acroanesthesia is 98.5%. The clinical treatment effect of the granular preparation of the invention applied after the operation of prolapse of lumbar intervertebral disc (PLID) is as follows: the recovery rate of the sample group of the invention is 86.7%, and the recovery rate of the control group is 61%.
This study is a phase II, randomized, double-blind, placebo-controlled, parallel group study in subjects with rheumatoid arthritis (RA) on stable doses of Enbrel. Subjects with an adequate response to Enbrel will be enrolled into the study. Subjects will be withdrawn from their Enbrel and randomized to receive 28 days of dosing with either GSK706769 or placebo followed by 28 days off-drug. This study is exploring a novel therapeutic paradigm for RA, remission maintenance. In such an approach, remission is induced and then the inducing agent is stopped and a maintenance agent is added. The clinical benefit would be derived from the fact that the remission agent may be easier to take (e.g. oral rather than parenteral), more durable in its maintenance of remission, and/or safer (e.g. no TB reactivation). This study directly explores remission maintenance. Specifically, in a randomised, double blind, placebo controlled study, RA patients in remission through an adequate response to Enbrel will be recruited. Enbrel has been selected as it has a relatively short half life and therefore it is more likely patients treated with placebo may have a higher incidence of relapse after 28 days than with other anti-TNF treatments. After withdrawal of Enbrel (and possibly other oral DMARDs), subjects will be randomised to receive GSK706769 or placebo for 28 days followed by a period of 28 days off treatment. It is hypothesized that GSK706769 will prevent any CCR5+ cells from returning into the synovium, thereby resulting in maintenance of the efficacy induced by Enbrel. In the placebo group, CCR5 cells may re-populate the synovium resulting in increased inflammation. Patients experiencing increased disease activity will be able to withdraw from the study and resume standard of care.
BACKGROUND: Obesity and its associated health complications have become a global public health concern, necessitating innovative approaches to weight management. One emerging area of research focuses on the influence of chronotype, an individual's preferred timing for daily activities, on eating habits, weight regulation, and metabolic health. Recent observational studies suggest that the misalignment between an individual's chronotype and external cues, such as meal timing, may contribute to metabolic dysregulation and obesity, but evidence from intervention studies is still limited. This study protocol describes a randomized controlled trial designed to explore the effects of a chronotype-adapted diet, compared with a diet with a conventional calorie distribution, on weight loss, cardiometabolic health, and gut microbiota composition.
METHODS: A total of 150 overweight/obese adults will be recruited for this 4-month parallel-group, randomized, two-arm, open-label, superiority trial with 1:1 allocation ratio. Participants will be randomly assigned to either the intervention group or the control group. The intervention group will receive a low-calorie chronotype-adapted diet with a calorie distribution adapted to the individual chronotype (morning or evening), optimizing meal timing according to their peak metabolic periods. The control group will follow a standardized low-calorie healthy eating plan without considering chronotype. Both diets will have equivalent daily calorie content, adjusted according to gender and starting weight. Anthropometric measurements, body composition, blood, and fecal samples will be obtained from each participant at the beginning and the end of the study. The primary outcome is weight change from baseline. Secondary outcomes are changes from baseline in body mass index (BMI), fat mass, lipid and glycemic profile, fecal microbiota profile, and short-chain fatty acids (SCFAs).
DISCUSSION: The results of this randomized controlled trial have the potential to advance our understanding of the complex interactions between chronotype, diet, body weight, and health outcomes. By providing evidence for personalized dietary interventions based on individuals' circadian preferences, this research could offer insights into personalized nutrition strategies. Such knowledge could guide the development of innovative dietary interventions to optimize the prevention and management of overweight and obesity, while also improving the risk profile of these individuals.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05941871. Registered on 18 May 2023.
Cellular senescence serves as a significant tumor suppression mechanism in mammals. Cellular senescence is induced in response to various stressors and acts as a safeguard against the uncontrolled proliferation of damaged cells that could lead to malignant transformation. Senescent cells also exhibit a distinctive feature known as the senescence-associated secretory phenotype (SASP), wherein they secrete a range of bioactive molecules, including pro-inflammatory cytokines, growth factors, and proteases. These SASP components have both local and systemic effects, influencing the surrounding microenvironment and distant tissues, and have been implicated in the processes of tissue aging and the development of chronic diseases. Recent studies utilizing senolysis models have shed light on the potential therapeutic implications of targeting senescent cells. The targeting of senescent cell may alleviate the detrimental effects associated with cellular senescence and its SASP components. Senolytics have shown promise in preclinical studies for treating age-related pathologies and chronic diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. Respiratory diseases have emerged as a significant global health concern, responsible for a considerable number of deaths worldwide. Extensive research conducted in both human subjects and animal models has demonstrated the involvement of cellular senescence in the pathogenesis of respiratory diseases. Chronic pulmonary conditions such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis have been linked to the accumulation of senescent cells. This review aims to present the findings from research on respiratory diseases that have utilized systems targeting senescent cells and to identify potential therapeutic strategies for the clinical management of these conditions. Geriatr Gerontol Int 2024; 24: 60-66.
BIA 2-093 300 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
The present invention relates to a fetal conversion plaster of sticking on an acupoint, which relates to a unilateral transdermal absorption patch of dried ginger. The sticking surface of sticking a supporting object has an annular soft lining object, and a protective layer which can be conveniently tore off is covered on the annular soft lining object. The present invention is characterized in that ginger mud made of excipient added with ginger powder is filled in a ring of the annular soft lining object. The present invention uses the pungent and thermal medicine properties to be stuck and applied to the Yin acupoint to realize the complete revolution of an embryo. The present invention has the characteristics of correct pharmacology, abundant medicinal resources, simple manufacture, convenient use and reliable curative effect; pregnant women can take the fetal conversion plaster by selves without pain and side effects, and can easily receive treatment, and the present invention is convenient for popularization and application. The present invention is particularly suitable to be popularized in countryside and remote regions.
The invention discloses a dexibuprofen sustained-release pellet and a preparation method thereof. The dexibuprofen sustained-release pellet comprises a celphere, a drug layer and an external coating. In the terms of the total weight of the pellet, the celphere accounts for 15 % to 30 %. The drug layer consists of dexibuprofen, a binding agent and talcum powder, wherein the dexibuprofen accounts for 70-85 %, the binding agent accounts for 1-10 %, and the talcum powder accounts for 0.1-3 %. The external coating consists of a coating material and the talcum powder, the coating material accounts for 0.5-3 % and the talcum powder accounts for 0.1-3 %. The invention further provides the preparation method of the dexibuprofen sustained-release pellet. In the invention, the dexibuprofen sustained-release pellet has the advantages of good stability, high bioavailability, good mobility and wide application prospect and is beneficial to subpackage of preparations or is further pressed in a form of a tablet.